AlphaGen
Access AlphaGen
Company Narratives

Ferozsons Laboratories Q3 FY26: Subsidiary Growth Lifts the Group, but Working Capital Absorbs Cash

Ferozsons’ Q3 FY26 group revenue and margins improved as BF Biosciences scaled, but higher commercial spending and working capital limited cash conversion.

Sep 21, 2026

Verdict

Ferozsons Laboratories’ March 2026 quarter was stronger at group level than the standalone top line suggests. Consolidated Q3 revenue rose 9.0% year on year to Rs5.55 billion and gross profit rose 21.3%, lifting gross margin by roughly 459 basis points to 45.3%. Yet consolidated operating profit increased only 1.8% and profit after tax increased just 2.2%, because the larger gross-profit pool was absorbed by much higher selling, distribution and administrative spending. The quarter therefore combined healthier product economics with heavier commercial investment.

The contrast between the parent and subsidiary is the central story. Standalone Q3 revenue fell 3.1% to Rs3.66 billion, partly because of lower medical-device sales and closure of the Pak-Afghan border. Management nevertheless says commercial in-market sales rose 5% on higher volumes rather than price increases. BF Biosciences, meanwhile, grew Q3 revenue 42.3% to Rs2.14 billion after Line II entered commercial operations. That subsidiary expansion explains why the consolidated group grew while the parent’s reported standalone revenue declined.

Results at a glance

  • Company Name: Ferozsons Laboratories Ltd
  • Ticker: FEROZ
  • Reporting period: Third quarter and nine months ended March 31, 2026.
  • Reporting basis: Unaudited condensed interim standalone and consolidated financial information in Pakistani rupees. The consolidated accounts include the 98%-owned Farmacia retail venture and 57.36%-owned BF Biosciences Limited. The June 30, 2025 comparative statement of financial position is audited.
  • Q3 FY26 consolidated: revenue Rs5.55bn, up 9.0%; gross profit Rs2.51bn, up 21.3%; operating profit Rs519.5m, up 1.8%; PAT Rs253.3m, up 2.2%; EPS attributable to owners Rs4.78 versus Rs4.59.
  • 9MFY26 consolidated: revenue Rs18.17bn, up 26.6%; gross profit Rs8.17bn, up 35.9%; operating profit Rs1.88bn, up 20.5%; PAT Rs919.7m, up 38.0%; EPS attributable to owners Rs16.92 versus Rs13.12.
  • Dividend: The Board approved no interim cash dividend for the period, unchanged from the comparable period.

These four are AlphaGen model outputs, not company-reported figures.

  • Alpha QoQ Score: 17.81
  • TTM Performance Score: 84.29
  • 3Y Business Perf Score: 71.5
  • Sector Leadership Score: 36.0807

What improved

The gross-margin expansion was the clearest operating improvement. Consolidated Q3 gross margin rose to about 45.3% from 40.7%, while standalone gross margin improved to about 42.1% from 40.3%. Management attributes the parent-company improvement to higher volumes and a more favorable sales mix. This matters because standalone revenue actually declined: the company generated slightly more gross profit from a smaller reported revenue base.

The nine-month trend is stronger still. Consolidated revenue increased 26.6% to Rs18.17 billion and gross profit increased 35.9% to Rs8.17 billion, taking gross margin to about 45.0% from 41.9%. Standalone nine-month revenue rose 10.5% and PAT increased 29.0% to Rs503.9 million. The parent has therefore already generated almost as much profit in nine months as it earned in all of FY2025, when PSX reports standalone PAT of about Rs528.2 million.

Finance cost also moved in the right direction. Standalone nine-month finance cost fell 37.4% to Rs223.7 million, and consolidated finance cost fell 37.6% to Rs296.3 million. Management links this to lower short-term borrowing during the period and an average decline of about 400 basis points in the policy rate. The benefit was material: on the standalone accounts, profit after tax grew much faster than operating profit.

BF Biosciences changed the group’s growth profile

BF Biosciences was the major growth engine. Its nine-month revenue rose 72% to Rs7.24 billion and PAT rose 45% to Rs464.9 million. In Q3 alone, revenue increased 42.3% to Rs2.14 billion and gross margin expanded to about 45.6% from 36.6%. The subsidiary says growth came primarily from higher volumes from existing and new products after commercial operations began on Line II, while mix and better capacity utilization improved factory-overhead absorption.

That operating leverage did not fully reach BF Biosciences’ bottom line in Q3. Selling and distribution expense more than doubled year on year and administrative expense also rose sharply as the subsidiary expanded field-force, marketing and headcount. As a result, BF Biosciences’ Q3 operating profit slipped about 2.4% and PAT declined about 5.5% despite the much stronger revenue and gross margin.

The same pattern is visible at consolidated level. Group Q3 gross profit increased by roughly Rs441 million year on year, but selling and distribution expense increased by about Rs349 million and administrative expense by about Rs49 million. Other income also declined. The result was only a modest increase in operating profit. Economically, Ferozsons is spending part of the benefit from better mix and subsidiary scale to build the commercial platform required to sustain higher volumes.

What weakened / needs attention

The first weakness is cash conversion. Consolidated nine-month net cash from operating activities fell to Rs143.3 million from Rs1.02 billion a year earlier, even though PAT rose sharply. Before working-capital movements, cash generation improved to Rs2.78 billion. The problem was a Rs2.55 billion working-capital absorption, led by inventory, trade receivables, and loans and advances.

Inventory absorbed about Rs1.39 billion of cash and trade receivables about Rs1.00 billion during the nine months. On the consolidated balance sheet, stock in trade increased 20.9% from June 2025 to Rs7.98 billion and trade debts increased 40.4% to Rs3.23 billion. Higher trade payables partly funded that build, but not enough to prevent operating cash conversion from weakening substantially.

The second issue is leverage at the period end. Consolidated short-term borrowings rose to Rs3.11 billion from Rs2.25 billion at June 2025, while the group’s cash-and-cash-equivalent deficit widened to Rs2.52 billion from Rs1.56 billion at the start of the period. Current liabilities rose faster than current assets, reducing the current ratio to about 1.79x from 1.94x. This does not erase the lower finance-cost benefit, because average borrowing and benchmark rates during the period matter more than one closing balance. It does, however, mean the March balance sheet is less comfortable than the income statement alone implies.

Capital expenditure adds another demand on cash. Consolidated purchases of property, plant and equipment were Rs926.6 million during the nine months, almost 89% above the comparable period. The accounts do not provide a clean bridge assigning this entire amount to specific expansion projects, so it would be inappropriate to assume all of the spending relates to BF Biosciences’ Line II. What is clear is that the group is simultaneously funding growth, carrying more working capital and investing in fixed assets.

Standalone Q3: lower reported sales, but better unit economics

The parent company’s Q3 revenue fell 3.1% to Rs3.66 billion. Management attributes that decline primarily to lower medical-device sales and the closure of the Pak-Afghan border. This is important because the headline revenue decline does not represent the whole domestic pharmaceutical franchise: management says commercial in-market sales grew 5%, driven by volume rather than price adjustment.

The parent’s in-market generic sales were up 20% over nine months, while institutional sales of generics and medical devices were down 9%. That mix shift helps explain why gross margin improved even with softer Q3 reported sales. Distribution expenses fell 1.6% in Q3, administrative expense was almost flat and finance cost fell 11.8%, allowing standalone PAT to rise 8.8% to Rs150.2 million.

The Afghanistan border disruption should be treated as an external channel constraint rather than a permanent change in the economics of the domestic business. Management specifically says it hurt exports in Q3 and expects the impact to persist if the situation remains unresolved. The next result should show whether reopening or normalization restores this sales channel, or whether the drag continues.

Sector context: price-led industry growth versus company-specific volume growth

Management estimates Pakistan’s pharmaceutical industry was growing at roughly 14% on a moving-annual-total basis, primarily because of price increases. That distinction is useful. Ferozsons says its own commercial in-market Q3 sales growth was volume-led rather than price-led, while BF Biosciences also attributes much of its growth to higher volumes following Line II commissioning.

Official manufacturing data provide a broader benchmark. Pakistan Bureau of Statistics reported overall large-scale manufacturing growth of 6.48% in July–March FY26, including a strong 11.09% year-on-year increase in March. That broader recovery does not by itself explain Ferozsons’ result: management’s own disclosures show the parent’s commercial growth was volume-led while the consolidated acceleration came disproportionately from BF Biosciences. The relevant conclusion is that company mix and capacity expansion mattered alongside the macro backdrop.

The regulatory setting also matters. Pakistan’s framework deregulated prices of non-essential medicines in February 2024, while essential medicines remain subject to the applicable pricing framework. That is relevant background for understanding why industry nominal growth can be price-led, but the company itself explicitly says its latest commercial in-market growth was not driven by a price adjustment.

Recurring versus non-recurring earnings

The recurring earnings engine is pharmaceutical and medical-device sales, gross margin, field-force and distribution spending, manufacturing utilization and financing cost. The Q3 gross-margin improvement at both the parent and BF Biosciences, the volume growth in in-market generics, and the commercial spending required to support that growth are therefore recurring operating economics.

There were investment and other-income items, but they were not the core reason for the result. Consolidated nine-month cash-flow adjustments include fair-value gains on short-term investments, realized investment gains and gains on disposal of property, plant and equipment. These are economically separate from medicine sales and should not be extrapolated as operating margin. At the same time, the group’s lower finance cost is partly macro-sensitive: it benefited from a lower average policy-rate environment rather than solely from permanent structural deleveraging.

The group also has non-controlling interests because Ferozsons owns 57.36% of BF Biosciences. Consolidated Q3 PAT was Rs253.3 million, but Rs45.5 million was attributable to non-controlling interests; Rs207.8 million was attributable to owners of Ferozsons. That distinction matters when comparing consolidated profit with EPS.

What changed versus the recent historical pattern

Ferozsons’ standalone business has been rebuilding earnings for several years. PSX annual history shows sales rising from Rs9.89 billion in FY2023 to Rs12.71 billion in FY2024 and Rs13.86 billion in FY2025, while PAT rose from Rs189.0 million to Rs400.1 million and then Rs528.2 million. The current nine-month standalone PAT of Rs503.9 million continues that improvement.

What is different in FY26 is the scale of the subsidiary contribution. BF Biosciences’ 72% nine-month revenue growth lifted consolidated sales far faster than the parent’s standalone sales. This creates a more diversified group earnings base, but it also brings a larger field-force, marketing, inventory, receivables and capex requirement. The next stage of the story is therefore not simply whether revenue grows; it is whether the expanded group can convert that growth into cash and preserve the margin gains.

What to monitor next

  • BF Biosciences conversion: whether strong Line II volume growth begins to translate into faster operating-profit and PAT growth after the current field-force and marketing expansion.
  • Standalone sales mix: whether domestic commercial generic volumes continue to grow and whether medical-device and institutional sales recover.
  • Afghanistan border: whether the export channel normalizes or remains a drag on parent-company revenue.
  • Gross margin: whether the parent can hold roughly 42% and the group around the mid-40s as APIs, packaging, freight and oil-linked costs evolve.
  • Working capital: inventory and receivables grew much faster than cash earnings. A sustainable next quarter should show better cash conversion without relying heavily on higher supplier balances.
  • Short-term borrowings and finance cost: closing short-term debt increased despite lower nine-month finance cost. The next accounts will show whether the March balance is temporary or becomes a renewed financing burden.
  • Capex: watch whether the higher investment level produces measurable capacity, efficiency or mix benefits and whether operating cash flow can fund it.
  • Commercial spending: selling and distribution costs absorbed much of the Q3 gross-profit improvement. The key test is whether that spending produces durable volume growth and operating leverage.

Overall, Ferozsons’ Q3 FY26 result is an operating-growth story with a cash-conversion caveat. BF Biosciences gave the consolidated group meaningful scale, while the standalone business defended and slightly improved profitability despite lower reported Q3 revenue. Gross margins improved and finance cost fell, but the benefits were partly reinvested in commercial expansion and working capital. The next result will be stronger evidence of quality if the subsidiary’s volume growth continues while receivables, inventory and short-term borrowing stop rising faster than cash generation.

Sources

Explore more research

All articles